CRISPR patent dispute not over yet as Emmanuelle Charpentier, universities appealnews2022-04-04T20:12:17+00:00April 4th, 2022|FierceBiotech|
Through ‘serial de-risking,’ Sage is getting closer to building an Alzheimer’s contendernews2022-04-04T19:31:42+00:00April 4th, 2022|FierceBiotech|
ACC: Ionis-AstraZeneca antisense drug reduces troublesome cholesterol in phase 2bnews2022-04-04T14:21:54+00:00April 4th, 2022|FierceBiotech|
Big Pharma-backed $1B AMR Action Fund picks 1st antimicrobial biotech investmentsnews2022-04-04T13:47:52+00:00April 4th, 2022|FierceBiotech|
Obesity may alter inflammation on a molecular level, throwing current treatments into questionnews2022-04-04T12:28:16+00:00April 4th, 2022|FierceBiotech|
FDA puts Curis’ leukemia trial on partial hold after patient death spurs review of muscle breakdownnews2022-04-04T11:54:51+00:00April 4th, 2022|FierceBiotech|
Novartis says bye to Tsai as restructuring triggers the return of a familiar facenews2022-04-04T08:54:17+00:00April 4th, 2022|FierceBiotech|
Legend Biotech CSO abruptly leaves Johnson & Johnson’s CAR-T partner he co-foundednews2022-04-02T01:11:13+00:00April 2nd, 2022|FierceBiotech|
SAB vows to plow ahead with COVID-19 therapy after NIH drops outnews2022-04-01T14:06:34+00:00April 1st, 2022|FierceBiotech|
Leaping forward: Bayer VC arm commits $1.4B to double investment pace through 2024news2022-04-01T14:02:52+00:00April 1st, 2022|FierceBiotech|
